Efficacy and Safety of Diphereline 11.25 Mg, Microrelin 11.25 Mg, and Microrelin 3.75 Mg in Premenopausal Patients With Breast Cancer: A Non-Inferiority Randomized Clinical Trial

Efficacy and Safety of Diphereline 11.25 Mg, Microrelin 11.25 Mg, and Microrelin 3.75 Mg in Premenopausal Patients With Breast Cancer: A Non-Inferiority Randomized Clinical Trial Publisher Pubmed

Najafi S¹ ; Ansari M¹ ; Omidi Z¹ ; Olfatbakhsh A¹ ; Moghadam S¹ ; Hashemi EOS¹ ; Najafi N² ; Haghighat S¹

Show Affiliations

1. Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran
2. Faculty of life sciences and biotechnology, Shahid Beheshti University, Tehran, Iran

Source: BMC Cancer Published:2023

Abstract

Background: Diphereline is a Gonadotropin-Releasing Hormone agonist commonly used in patients with breast cancer. This study aimed to compare the efficacy and safety of one-month and three-month Microrelin injections produced by Homa Pharmed Company with three-month Diphereline injections manufactured by IPSEN, France. Methods: The study was a non-inferiority randomized clinical trial conducted between 2019 and 2023 on premenopausal women candidates for endocrine therapy. The participants were randomly assigned in blocks of six to one of three groups named A (Diphereline 11.25 mg), B (Microrelin 11.25 mg), and C (Microrelin 3.75 mg). The participants’ menopausal symptoms, estradiol, and FSH serum levels were recorded in three-month intervals for one year. The efficacy of each medication and its side effects were compared among the three groups by statistical analysis during the one-year follow-up. Results: The study included 133 patients with breast cancer. A decreasing trend in the serum levels of FSH and estradiol and an increasing trend of menopausal symptoms were recorded during the study. No specific side effects leading to drug disruption, hospitalization, or exclusion from the study were observed. Adjusting the effect of study group and time showed no significant changes in estradiol levels between groups B (p = 0.506) and C (p = 0.607) and group A. Also, serum FSH changes between groups B (p = 0.132) and C (p = 0.104) compared to group A were not significant. Moreover, the menopausal symptoms during the one-year follow-up did not significantly increase in group B (p = 0.108) and C (p = 0.113) compared to group A. Conclusions: It can be concluded that injections of both Microrelin 11.25 mg and 3.75 mg, produced by Homa Pharmed, Iran, are non-inferior in terms of effectiveness and incidence of menopausal symptoms compared to Diphereline, manufactured by IPSEN, France. Trial registration: IRCT.ir, IRCT20201227049847N1; Registered on 09/01/2021. © 2023, The Author(s).

2. The Role of Hypoxia-Inducible Factors in Breast Cancer Stem Cell Specification, Pathology Research and Practice (2023)

3. Association of Serpind1 Expression With Grade, Stage and Presence of Metastasis in Breast Cancer, Indian Journal of Biochemistry and Biophysics (2021)

4. The Global Incidence, Mortality, and Burden of Breast Cancer in 2019: Correlation With Smoking, Drinking, and Drug Use, Frontiers in Oncology (2022)

5. Teriflunomide Loaded Spion Nanoparticles Induced Apoptosis in Mda-Mb-231 Breast Cancer Cells, Journal of Cluster Science (2023)

6. Pi3k/Akt/Mtor Signaling Pathway Modulation by Circular Rnas in Breast Cancer Progression, Pathology Research and Practice (2023)

Experts (# of related papers)

View all Related Experts

Nasim Vahidfar (1)

Alireza Abdollahi (1)

Style	Citing Format
MLA	Najafi S, et al.. "Efficacy and Safety of Diphereline 11.25 Mg, Microrelin 11.25 Mg, and Microrelin 3.75 Mg in Premenopausal Patients With Breast Cancer: A Non-Inferiority Randomized Clinical Trial." BMC Cancer, vol. 23, no. 1, 2023, pp. -.
APA	Najafi S, Ansari M, Omidi Z, Olfatbakhsh A, Moghadam S, Hashemi EOS, Najafi N, Haghighat S (2023). Efficacy and Safety of Diphereline 11.25 Mg, Microrelin 11.25 Mg, and Microrelin 3.75 Mg in Premenopausal Patients With Breast Cancer: A Non-Inferiority Randomized Clinical Trial. BMC Cancer, 23(1), -.
Chicago	Najafi S, Ansari M, Omidi Z, Olfatbakhsh A, Moghadam S, Hashemi EOS, Najafi N, Haghighat S. "Efficacy and Safety of Diphereline 11.25 Mg, Microrelin 11.25 Mg, and Microrelin 3.75 Mg in Premenopausal Patients With Breast Cancer: A Non-Inferiority Randomized Clinical Trial." BMC Cancer 23, no. 1 (2023): -.
Harvard	Najafi S et al. (2023) 'Efficacy and Safety of Diphereline 11.25 Mg, Microrelin 11.25 Mg, and Microrelin 3.75 Mg in Premenopausal Patients With Breast Cancer: A Non-Inferiority Randomized Clinical Trial', BMC Cancer, 23(1), pp. -.
Vancouver	Najafi S, Ansari M, Omidi Z, Olfatbakhsh A, Moghadam S, Hashemi EOS, et al.. Efficacy and Safety of Diphereline 11.25 Mg, Microrelin 11.25 Mg, and Microrelin 3.75 Mg in Premenopausal Patients With Breast Cancer: A Non-Inferiority Randomized Clinical Trial. BMC Cancer. 2023;23(1):-.
BibTex	@article{ author = {Najafi S and Ansari M and Omidi Z and Olfatbakhsh A and Moghadam S and Hashemi EOS and Najafi N and Haghighat S}, title = {Efficacy and Safety of Diphereline 11.25 Mg, Microrelin 11.25 Mg, and Microrelin 3.75 Mg in Premenopausal Patients With Breast Cancer: A Non-Inferiority Randomized Clinical Trial}, journal = {BMC Cancer}, volume = {23}, number = {1}, pages = {-}, year = {2023} }
RIS	TY - JOUR AU - Najafi S AU - Ansari M AU - Omidi Z AU - Olfatbakhsh A AU - Moghadam S AU - Hashemi EOS AU - Najafi N AU - Haghighat S TI - Efficacy and Safety of Diphereline 11.25 Mg, Microrelin 11.25 Mg, and Microrelin 3.75 Mg in Premenopausal Patients With Breast Cancer: A Non-Inferiority Randomized Clinical Trial JO - BMC Cancer VL - 23 IS - 1 SP - EP - PY - 2023 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract